IRIX

IRIDEX Corporation($IRIX) Executives and Directors Accumulate $66,790 in Shares Over Nine Days as Stock Rebounds 65% from March Lows

04/29/2025 23:46

As shares of ophthalmic device maker IRIDEX Corporation ($IRIX) show signs of recovery following a recent steep decline, company executives and directors have been actively purchasing significant amounts of company stock. After a steady downward trend over the past year, $IRIX shares plummeted in mid-March 2025, reaching a low of $0.79 per share on March 20. However, the stock has since rebounded, climbing to $1.30 as of April 28, representing a roughly 65% increase from its recent bottom. Notably, this rebound coincides with concentrated insider buying from the company's key leadership. In just nine days, from April 21 to April 29, 2025, four insiders collectively purchased approximately 57,010 shares worth about $66,790. Director William Moore acquired a total of 20,000 shares at $1.05 and $1.08 on April 21 and 22, respectively. According to company filings, these shares are indirectly held through the William M. Moore Trust and Patricia A. Moore Trust. Fellow director Scott Shuda purchased 21,457 shares at $1.20 per share on April 24. Among the executive team, President Patrick Mercer bought a total of 7,546 shares across two transactions on April 24 and 28, while CFO Romeo Dizon made four separate purchases totaling 8,007 shares between April 21 and 29. Notably, Dizon progressively increased his purchase volume as the share price rose. IRIDEX Corporation, headquartered in California, specializes in ophthalmic medical devices, particularly laser systems for treating glaucoma and retinal disorders. For fiscal year 2024, the company reported total revenue of $48.7 million, a 4.2% decrease from the previous year, with a net loss of approximately $8.91 million. With a market capitalization of about $15.8 million, it falls into the small-cap category. The company recently secured a strategic $10 million investment from Novel Inspiration International Co. to stabilize its financial position and support growth initiatives. In Q4 2024, IRIDEX achieved positive adjusted EBITDA of $0.4 million, benefiting from cost reduction efforts. This concentrated insider buying occurred during a period of significant volatility in U.S. equity markets. In early April 2025, escalating trade tensions between the U.S. and China caused major indices to drop more than 5% on April 4, followed by a dramatic rebound on April 9 when President Trump announced a 90-day tariff pause, triggering a 9.5% surge in the S&P 500. Substantial insider purchases typically indicate that management believes the company's stock is undervalued or that they have confidence in future business prospects. Currently, IRIDEX trades at a Price/Sales ratio of 0.44, suggesting the stock is considerably undervalued relative to its sales. Historically, concentrated insider buying often precedes stock appreciation, though IRIDEX's high debt-to-equity ratio (221.41%) and negative operating cash flow (-$7.29 million) remain risk factors to consider. The company has projected Q1 2025 revenue between $11.8 million and $12.0 million and aims to achieve cash flow breakeven and positive adjusted EBITDA in 2025. The recent share purchases by insiders appear to reflect confidence in this recovery trajectory.

You can receive notifications when news is published.